Table 2 Characteristics of patients in the abnormal bone mass and normal bone mass groups
From: Prediction of abnormal bone mass with a pericoronary adipose tissue Attenuation model
Characteristics | Overall (n = 361) | Normal bone mass (n = 193) | Abnormal bone mass (n = 168) | p value |
|---|---|---|---|---|
Age, years | 59.89 ± 11.08 | 54.32 ± 9.49 | 66.30 ± 9.18 | 0.001 |
Male | 214 (0.59) | 130 (0.67) | 84 (0.50) | 0.001 |
BMI, kg/m2 | 24.93 ± 3.42 | 25.55 ± 3.50 | 24.21 ± 3.18 | 0.001 |
Smoking | 126 (0.35) | 63 (0.33) | 63 (0.38) | 0.336 |
Drinking | 138 (0.38) | 75 (0.39) | 63 (0.38) | 0.792 |
Hypertension | 203 (0.56) | 99 (0.51) | 104 (0.62) | 0.043 |
CAD-RADS category | Â | Â | Â | 0.005 |
CAD-RADS ≤ 2 | 153 (0.42) | 95 (0.49) | 58 (0.35) |  |
CAD-RADS >2 | 208 (0.58) | 98 (0.51) | 110 (0.65) | Â |
Diabetes | 105 (0.29) | 54 (0.28) | 51 (0.30) | 0.621 |
Microvascular complications | 50 (0.14) | 24 (0.12) | 26 (0.15) | 0.406 |
Statins | 182 (0.50) | 130 (0.67) | 52 (0.31) | 0.001 |
Diuretics | 26 (0.07) | 10 (0.05) | 16 (0.10) | 0.112 |
β-blockers | 57 (0.16) | 35 (0.18) | 22 (0.13) | 0.191 |
CCB | 76 (0.21) | 27 (0.14) | 49 (0.29) | 0.001 |
ACEI | 87 (0.24) | 47 (0.24) | 40 (0.24) | 0.905 |
Insulins | 23 (0.06) | 15 (0.08) | 8 (0.05) | 0.244 |
Insulin secreting agent | 23 (0.06) | 6 (0.03) | 17 (0.10) | 0.006 |
Biguanides | 45 (0.12) | 19 (0.10) | 26 (0.15) | 0.107 |
α-Glucosidase inhibitors | 17 (0.05) | 5 (0.03) | 12 (0.07) | 0.042 |
SGLT-2 inhibitors | 18 (0.05) | 11 (0.06) | 7 (0.04) | 0.506 |
Dyslipidemia | 196 (0.54) | 105 (0.54) | 91 (0.54) | 0.964 |
GLU, mmol/L | 6.01 ± 2.35 | 6.02 ± 2.55 | 6.01 ± 2.11 | 0.966 |
Ca, mmol/L | 2.26 ± 0.14 | 2.27 ± 0.13 | 2.25 ± 0.15 | 0.133 |
P, mmol/L | 1.16 ± 0.19 | 1.15 ± 0.18 | 1.17 ± 0.19 | 0.330 |
RCAPCAT, HU | -88.30 ± 9.72 | -93.05 ± 7.69 | -82.86 ± 8.95 | 0.001 |
LADPCAT, HU | -86.14 ± 8.95 | -88.91 ± 8.62 | -82.95 ± 8.25 | 0.001 |
LCXPCAT, HU | -83.17 ± 9.26 | -86.03 ± 9.09 | -79.89 ± 8.35 | 0.001 |